Display options
Cite
Bond DR, Kahl R, Brzozowski JS, et al. Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth. Cancers (Basel). 2020;12(4)doi: 10.3390/cancers12040795.
Bond, D. R., Kahl, R., Brzozowski, J. S., Jankowski, H., Naudin, C., Pariyar, M., Avery-Kiejda, K. A., Scarlett, C. J., Boucheix, C., Muller, W. J., Ashman, L. K., Cairns, M. J., Roselli, S., & Weidenhofer, J. (2020). Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth. Cancers, 12(4), . https://doi.org/10.3390/cancers12040795
Bond, Danielle R, et al. "Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth." Cancers vol. 12,4 (2020). doi: https://doi.org/10.3390/cancers12040795
Bond DR, Kahl R, Brzozowski JS, Jankowski H, Naudin C, Pariyar M, Avery-Kiejda KA, Scarlett CJ, Boucheix C, Muller WJ, Ashman LK, Cairns MJ, Roselli S, Weidenhofer J. Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth. Cancers (Basel). 2020 Mar 26;12(4). doi: 10.3390/cancers12040795. PMID: 32224917; PMCID: PMC7226392.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Mar 26;12(4). doi: 10.3390/cancers12040795.

Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth.

Cancers

Danielle R Bond, Richard Kahl, Joshua S Brzozowski, Helen Jankowski, Crystal Naudin, Mamta Pariyar, Kelly A Avery-Kiejda, Christopher J Scarlett, Claude Boucheix, William J Muller, Leonie K Ashman, Murray J Cairns, Séverine Roselli, Judith Weidenhofer

Affiliations

  1. School of Biomedical Science and Pharmacy, The University of Newcastle and Hunter Medical Research Institute (HMRI), Newcastle, NSW 2308, Australia.
  2. Department of Pediatrics, Emory University, Atlanta, GA 30322, USA.
  3. School of Environmental and Life Sciences, The University of Newcastle and Hunter Medical Research Institute (HMRI), Newcastle, NSW 2308, Australia.
  4. INSERM U935, Université Paris-Sud, Bâtiment Lavoisier, 14 Avenue Paul-Vaillant-Couturier, F-94800 Villejuif, France.
  5. Molecular Oncology Group, Department of Biochemistry, McGill University, Montreal, Quebec, H3A 1A3, Canada.
  6. Centre for Brain and Mental Health Research, The University of Newcastle, Newcastle, NSW 2308, Australia.

PMID: 32224917 PMCID: PMC7226392 DOI: 10.3390/cancers12040795

Abstract

Breast cancer is the most commonly diagnosed and the second leading cause of cancer-related mortality among women worldwide. miR-518f-5p has been shown to modulate the expression of the metastasis suppressor CD9 in prostate cancer. However, the role of miR-518f-5p and CD9 in breast cancer is unknown. Therefore, this study aimed to elucidate the role of miR-518f-5p and the mechanisms responsible for decreased CD9 expression in breast cancer, as well as the role of CD9 in de novo tumor formation and metastasis. miR-518f-5p function was assessed using migration, adhesion, and proliferation assays. miR-518f-5p was overexpressed in breast cancer cell lines that displayed significantly lower CD9 expression as well as less endogenous CD9 3'UTR activity, as assessed using qPCR and dual luciferase assays. Transfection of miR-518f-5p significantly decreased CD9 protein expression and increased breast cell migration in vitro. Cd9 deletion in the MMTV/PyMT mouse model impaired tumor growth, but had no effect on tumor initiation or metastasis. Therefore, inhibition of miR-518f-5p may restore CD9 expression and aid in the treatment of breast cancer metastasis.

Keywords: CD9; breast cancer; miR-518f-5p; migration; regulation

References

  1. Oncotarget. 2015 Apr 10;6(10):7970-91 - PubMed
  2. Eur J Cell Biol. 2010 Nov;89(11):843-52 - PubMed
  3. Br J Cancer. 2018 Mar 20;118(6):813-819 - PubMed
  4. Carcinogenesis. 2012 Jan;33(1):77-83 - PubMed
  5. BMC Cancer. 2010 Apr 06;10:126 - PubMed
  6. Clin Cancer Res. 2005 Jun 15;11(12):4357-64 - PubMed
  7. Histopathology. 2017 Jun;70(7):1155-1165 - PubMed
  8. Oncogene. 2017 Mar;36(11):1461-1473 - PubMed
  9. Anticancer Res. 2012 Dec;32(12):5211-20 - PubMed
  10. DNA Cell Biol. 2015 Jun;34(6):437-57 - PubMed
  11. Int J Cancer. 2013 Oct 15;133(8):1803-12 - PubMed
  12. ISRN Oncol. 2012;2012:493283 - PubMed
  13. Genome Biol. 2014;15(9):445 - PubMed
  14. Nucleic Acids Res. 2017 Jan 4;45(D1):D183-D189 - PubMed
  15. J Carcinog. 2016 Feb 12;15:1 - PubMed
  16. Nat Rev Cancer. 2009 Jan;9(1):40-55 - PubMed
  17. J Cell Sci. 2012 Feb 1;125(Pt 3):649-61 - PubMed
  18. World J Gastroenterol. 2015 Mar 21;21(11):3206-13 - PubMed
  19. Sci Rep. 2017 Oct 5;7(1):12708 - PubMed
  20. CA Cancer J Clin. 2020 Jan;70(1):7-30 - PubMed
  21. Int J Oncol. 1997 Nov;11(5):1045-51 - PubMed
  22. Oncotarget. 2017 Dec 7;9(2):1980-1991 - PubMed
  23. Breast Cancer Res Treat. 2016 Dec;160(3):439-446 - PubMed
  24. PLoS One. 2013 Apr 17;8(4):e61834 - PubMed
  25. Cancer Res. 1995 Sep 15;55(18):4127-31 - PubMed
  26. Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7069-E7076 - PubMed
  27. Clin Exp Metastasis. 2005;22(1):59-67 - PubMed
  28. Cancer. 1990 Dec 1;66(11):2390-4 - PubMed
  29. Cancer Res. 1996 Mar 15;56(6):1244-9 - PubMed
  30. Asia Pac J Clin Oncol. 2018 Dec;14(6):383-391 - PubMed
  31. Transgenic Res. 2007 Apr;16(2):193-201 - PubMed
  32. BMC Cancer. 2014 Jul 11;14:509 - PubMed
  33. Nucleic Acids Res. 2014 Aug;42(14):9195-208 - PubMed
  34. Cancer Res. 2007 Feb 15;67(4):1744-9 - PubMed
  35. Biochem Soc Trans. 2011 Apr;39(2):563-7 - PubMed
  36. Mol Cell Biol. 1992 Mar;12(3):954-61 - PubMed
  37. Science. 2000 Jan 14;287(5451):319-21 - PubMed
  38. Elife. 2015 Aug 12;4: - PubMed
  39. Am J Pathol. 1998 Sep;153(3):973-83 - PubMed

Publication Types

Grant support